d[Cha4]-AVP

Discontinued Product

3126 has been discontinued.

View all Vasopressin Receptors products.
说明: Potent and selective human V1B agonist
说明书
引用文献 (1)
评论
文献 (1)

生物活性 for d[Cha4]-AVP

d[Cha4]-AVP is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.

技术数据 for d[Cha4]-AVP

分子量 1094.31
公式 C50H71N13O11S2
序列 XYFXNCPRG

(Modifications: X-1 = Mpr, X-4 = Cha, Gly-9 = C-terminal amide, Disulfide bridge between X-1 - Cys-6)

储存 Store at -20°C
CAS Number 500170-27-4
PubChem ID 44419028
InChI Key ZKYCVZNKBXGNEK-ZTYVOHGWSA-N
Smiles NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CC(N)=O)C(=O)N1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for d[Cha4]-AVP

分析证书/产品说明书
选择另一批次:

按产品操作查看相关产品

查看全部 Vasopressin Receptor Agonists

关键词: d[Cha4]-AVP, d[Cha4]-AVP supplier, Potent, selective, human, V1b, agonists, V2, Receptors, Vasopressin, 3126, Tocris Bioscience

1 篇 d[Cha4]-AVP 的引用文献

引用文献是使用了 Tocris 产品的出版物。 d[Cha4]-AVP 的部分引用包括:

Perígolo-Vicente et al (2014) IL-6, A1 and A2aR: a crosstalk that modulates BDNF and induces neuroprotection. Biochem Biophys Res Commun 449 477 PMID: 24845382


d[Cha4]-AVP 的评论

目前没有该产品的评论。 Be the first to review d[Cha4]-AVP and earn rewards!

Have you used d[Cha4]-AVP?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.